Article3 Biotech2025
Fujin Shengji Powder promotes healing of stage 3 pressure injury wounds in rats by modulating angiogenesis and inflammatory effects.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the role of Fujin Shengji Powder (FJSJP) in promoting the healing of stage 3 pressure injury (PI) wounds and potential mechanisms. High-performance liquid chromatography was used to identify active components in FJSJP. A rat model of stage 3 PI wounds was induced via ischemia-reperfusion (I/R) injury. After successful modeling, rats in the control group received no treatment, while the positive group, negative group, and FJSJP group applied rb-bFGFG, vaseline, FJSJP to the wound, respectively, covering the wound by 2 mm continuously for 14 days. Results showed that the wound healing rate on days 3, 7, and 14 was higher in the FJSJP group than in the control groups, with complete re-epithelialization and evident regeneration of skin structures. Furthermore, FJSJP increased CD31 positive expression and elevated mRNA and protein levels of VEGF, VEGFR2, and ERK1/2 at the wound site. The anti-inflammatory effect was confirmed by reduced CD86 positive expression and downregulated TNF-α and IL-6. In summary, topical application of FJSJP can effectively treat stage 3 PI wounds in rats, providing new insights and evidence for its role in accelerating wound healing, promoting angiogenesis, and reducing inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.